<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03446547</url>
  </required_header>
  <id_info>
    <org_study_id>2016-005225-37</org_study_id>
    <nct_id>NCT03446547</nct_id>
  </id_info>
  <brief_title>Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)</brief_title>
  <acronym>ASTEROID</acronym>
  <official_title>Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736). An Open Label Randomized Phase II Trial With Durvalumab Following Stereotactic Body Radiotherapy (SBRT) in Patients With Stage I Non-small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vastra Gotaland Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vastra Gotaland Region</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized multicentre open label phase II study of Durvalumab following&#xD;
      Stereotactic Body Radiotherapy (SBRT) in patients with T1-2N0M0 NSCLC.&#xD;
&#xD;
      Patients will be randomized 1:1 to follow up or receiving Durvalumab every 4th week for 12&#xD;
      months&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized multicentre open label phase II study of the PDL1 inhibitor Durvalumab&#xD;
      following SBRT in patients with T1-2N0M0 NSCLC. It will enroll 106 patients aiming at a&#xD;
      minimum of 5 subjects per site. The subjects will be randomized in a 1:1 fashion with&#xD;
      performance status, gender and T-stage as stratification factors. Patients with peripheral&#xD;
      lung tumors will receive SBRT usually between 3 and 4 fractions. The group randomized to&#xD;
      immunotherapy will then receive Durvalumab, given with a fixed dose of 1500 mg i.v. every&#xD;
      fourth week during 12 months. Both arms will be assessed according to the same follow-up&#xD;
      schedule with radiology every third month.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2017</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TTP</measure>
    <time_frame>From date of randomization until the date of first documented progression, assessed up to 60 months</time_frame>
    <description>Time to progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>From date of randomization until the date of death from any cause, assessed up to 60 months</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LC</measure>
    <time_frame>Assessed at scheduled timepoints every 3-6 months through study completion (60 months)</time_frame>
    <description>Local control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL</measure>
    <time_frame>Measured at baseline and at three timepoints (6, 12 and 20 months)</time_frame>
    <description>QoL by LCSS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTP by PDL1 expression</measure>
    <time_frame>From date of randomization until the date of first documented progression, assessed up to 60 months</time_frame>
    <description>Time to progression related to level of PDL1expression</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>NSCLC, Stage I</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>SBRT and follow-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SBRT followed by Durvalumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>durvalumab 1500 mg i.v. every fourth week for 12 months</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Medi4736</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent obtained from the subject prior to performing any protocol-&#xD;
             related procedures, including screening evaluations&#xD;
&#xD;
          -  Histological or cytological diagnosis of NSCLC&#xD;
&#xD;
          -  Stage I-IIA tumours ≤ 5 cm&#xD;
&#xD;
          -  Peripheral tumours&#xD;
&#xD;
          -  Medically inoperable patients or patients refusing surgery&#xD;
&#xD;
          -  Received no prior chemotherapy or radiation therapy for NSCLC&#xD;
&#xD;
          -  Age &gt; 18 years at time of study entry, no upper age limit&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  Adequate normal organ and marrow function as defined below:&#xD;
&#xD;
          -  Haemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (&gt; 1500 per mm3)&#xD;
&#xD;
          -  Platelet count ≥ 100 x 109/L (&gt;100,000 per mm3)&#xD;
&#xD;
          -  Serum bilirubin ≤ 1.5 x institutional upper limit of normal (ULN)&#xD;
&#xD;
          -  AST/ALT ≤ 2.5 x institutional upper limit of normal&#xD;
&#xD;
          -  Serum creatinine CL&gt;40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault&#xD;
             1976) or by chrome-EDTA or Iohexol clearance&#xD;
&#xD;
          -  Evidence of post-menopausal status or negative urinary or serum pregnancy test for&#xD;
             female pre-menopausal subjects&#xD;
&#xD;
          -  Subject is willing and able to comply with the protocol for the duration of the study&#xD;
             including undergoing treatment and scheduled visits and examinations including follow&#xD;
             up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Centrally located tumours&#xD;
&#xD;
          -  No regional or distant metastases are allowed (i.e. no stage II-IV disease)&#xD;
&#xD;
          -  Oxygen usage or a FEV1 &lt; 0.7 L and CO diffusion capacity &lt; 30%&#xD;
&#xD;
          -  Involvement in the planning and/or conduct of the study (applies to both AstraZeneca&#xD;
             staff and/or staff at the study site). Previous enrollment in the present study&#xD;
&#xD;
          -  Participation in another clinical study with an investigational product during the&#xD;
             last 4 weeks&#xD;
&#xD;
          -  Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab&#xD;
&#xD;
          -  Second primary residual malignancy. Other malignancy diagnosed and treated &gt; 5 years&#xD;
             ago without relapse is allowed. (Carcinoma in situ of the cervix or adequately treated&#xD;
             basal cell carcinoma of the skin &lt; 5 years are allowed)&#xD;
&#xD;
          -  Receipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy,&#xD;
             endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal&#xD;
             antibodies, other investigational agent) 28 days prior to the first dose of study drug&#xD;
&#xD;
          -  Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from 3&#xD;
             electrocardiograms (ECGs) using Frediricia's Correction&#xD;
&#xD;
          -  Current or prior use of immunosuppressive medication within 14 days before the first&#xD;
             dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or&#xD;
             systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of&#xD;
             prednisone, or an equivalent corticosteroid&#xD;
&#xD;
          -  Active or prior documented autoimmune or inflammatory disorders . The following are&#xD;
             exceptions to this criterion:&#xD;
&#xD;
               -  Subjects with vitiligo or alopecia&#xD;
&#xD;
               -  Subjects with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone&#xD;
                  replacement&#xD;
&#xD;
               -  Any chronic skin condition that does not require systemic therapy&#xD;
&#xD;
               -  Subjects without active disease in the last 5 years may be included but only&#xD;
                  after consultation with the study physician&#xD;
&#xD;
               -  Subjects with celiac disease controlled by diet alone&#xD;
&#xD;
          -  History of primary immunodeficiency&#xD;
&#xD;
          -  History of allogeneic organ transplant&#xD;
&#xD;
          -  History of hypersensitivity to durvalumab or any excipient&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure (NYHA III-IV), uncontrolled&#xD;
             hypertension, unstable angina pectoris, interstitial lung disease, cardiac arrhythmia,&#xD;
             active peptic ulcer disease, active bleeding diatheses&#xD;
&#xD;
          -  Active infection including tuberculosis (clinical evaluation that includes clinical&#xD;
             history, physical examination and radiographic findings, and TB testing in line with&#xD;
             local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result),&#xD;
             hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Subjects&#xD;
             with a past or resolved HBV infection (defined as the presence of hepatitis B core&#xD;
             antibody [anti-HBc] and absence of HBsAg) are eligible. Subjects positive for&#xD;
             hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative&#xD;
             for HCV RNA&#xD;
&#xD;
          -  Receipt of live attenuated vaccination within 30 days prior to study entry or within&#xD;
             30 days of receiving durvalumab&#xD;
&#xD;
          -  Female subjects who are pregnant or breastfeeding or male or female subjects of&#xD;
             reproductive potential who are not willing to employ effective birth control from&#xD;
             screening to 90 days after the last dose of durvalumab monotherapy.&#xD;
&#xD;
          -  Any condition that, in the opinion of the investigator, would interfere with&#xD;
             evaluation of study treatment or interpretation of patient safety or study results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Hallqvist, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Göteborg University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas Hallqvist, PhD</last_name>
    <phone>+46-31342</phone>
    <phone_ext>7954</phone_ext>
    <email>andreas.hallqvist@vgregion.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annika Baan</last_name>
    <phone>+46-70</phone>
    <phone_ext>0906097</phone_ext>
    <email>annika.baan@vgregion.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Helsinki</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anu Anttonen</last_name>
      <email>anu.anttonen@hus.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept of Oncology</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanja Skyttä</last_name>
    </contact>
    <contact_backup>
      <email>tanja.skytta@pshp.fi</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Turku</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Silvoniemi</last_name>
      <email>Maria.Silvoniemi@tyks.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept of Oncology</name>
      <address>
        <city>Vaasa</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antti Jekunen</last_name>
    </contact>
    <contact_backup>
      <email>antti.jekunen@vshp.fi</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Dept of Oncology</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Åslaug Helland</last_name>
      <email>AHH@ous-hf.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept of pulmonary medicine</name>
      <address>
        <city>Tromsø</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Helbekkmo</last_name>
      <email>Nina.Helbekkmo@unn.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept of Oncology</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bjørn Henning Grønberg</last_name>
      <email>bjorn.h.gronberg@ntnu.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ålesund</name>
      <address>
        <city>Ålesund</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Øyvind Yksnøy</last_name>
      <email>Oyvind.Yksnoy@helse-mr.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept of pulmonary medicine</name>
      <address>
        <city>Gävle</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hirsch Koyi</last_name>
      <email>hirsh.koyi@regiongavleborg.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Oncology</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Hallqvist, PhD</last_name>
      <email>andreas.hallqvist@vgregion.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept of pulmonary medicine</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders Wikström</last_name>
      <email>anders.vikstrom@regionostergotland.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunderbyn</name>
      <address>
        <city>Luleå</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lina Lindberg</last_name>
    </contact>
    <contact_backup>
      <email>lina.h.lindberg@norrbotten.se</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Dept of pulmonary medicine</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Planck, Ass. prof.</last_name>
      <email>maria.planck@med.lu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept of Oncology</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luigi De Petris, PhD</last_name>
      <email>luigi.depetris@sll.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Oncology</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikael Johansson, Ass. Prof.</last_name>
      <email>mikael.b.johansson@umu.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 11, 2018</study_first_submitted>
  <study_first_submitted_qc>February 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2018</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vastra Gotaland Region</investigator_affiliation>
    <investigator_full_name>Andreas Hallqvist</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>SBRT</keyword>
  <keyword>Immunotherapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Will be available later on</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

